中国人寿、新华保险等大型保险公司在2026年上半年业绩实现快速增长。其中，中国人寿预计归母净利润1289.33亿元至1371亿元，同比增长约215%至235%[1]；新华保险预计归母净利润207.2亿元至236.8亿元，同比增长40%至60%[1]。这波增长的核心驱动力来自二季度的权益投资收益。中国人寿二季度净利润达1088.6亿元至1170.3亿元，同比增长758.5%至823%[1]，新华保险二季度净利润为142.2亿元至172亿元，同比增长59.4%至92.6%[1]。与此形成鲜明对比的是，一季度时这些公司在权益投资上遭遇亏损，其中中国人寿公允价值亏损428.6亿元，中国平安亏损近500亿元，新华保险、中国人保亏损超200亿元[1]。
保险公司通过积极布局科技股和硬科技企业获得了这些投资收益。中国人寿旗下投资产品以615.9元/股的价格出售兆易创新111万股，套现6.82亿元[1]，并于7月27日通过保险资管产品布局长鑫科技上市[1]。在这一轮业绩反弹之后，这些保险公司表示将继续加码权益投资[1]。
Major Chinese insurance companies have reported dramatic earnings surges in the first half of 2026, with China Life Insurance posting projected net profits of between 128.93 billion and 137.1 billion yuan, representing a year-over-year increase of approximately 215% to 235% [1]. New China Life Insurance similarly announced estimated net profits ranging from 20.72 billion to 23.68 billion yuan, a gain of 40% to 60% compared with the same period last year [1].
The extraordinary growth has been substantially fueled by equity investment gains realized in the second quarter [1]. During this period alone, China Life Insurance's net profit reached between 108.86 billion and 117.03 billion yuan, marking a year-over-year surge of 758.5% to 823%, while New China Life Insurance recorded net profits of 14.22 billion to 17.2 billion yuan, up 59.4% to 92.6% [1]. The sharp turnaround follows substantial losses incurred in the first quarter, when China Life Insurance posted fair value losses of 428.6 billion yuan, and New China Life Insurance and China Pacific Insurance sustained losses exceeding 200 billion yuan [1]. China Life Insurance has actively deployed capital into technology enterprises, exemplified by its July 27 insurance asset management product investment in ChangXin Technology's listing [1]. The company has also monetized gains from existing positions, with its investment products selling 1.11 million shares of Zhaoji Innovation at 615.9 yuan per share, generating 682 million yuan in proceeds [1].
